SYF3a23a37607e2421d99691930d27b3069

Active Not RecruitingPhase 3

DupuytrEn Treatment EffeCtiveness Trial (DETECT)

Pirkanmaan hyvinvointialue Source

Compare

Study Type

interventional

Reported enrollment (type unavailable)

N/A

Locations

1 country

Sites

6

Brief Summary

To determine, which treatment strategy 1) primary PNF followed by surgical LF in patients who do not respond to PNF, 2) primary CCH followed by surgical LF in patients who do not respond to CCH or 3) LF as the primary (and secondary) treatment modality is the most efficacious and cost-effective in treating DC in 5-year follow-up.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: active not recruiting
Reported enrollment (type unavailable): Not reported
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 6 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
August 19, 2024
Actual (reported)

Conditions

Dupuytren's contracture

Outcome Measures

Primary Outcomes (1)

Success at five years

Interventions

COLLAGENASEType not reported

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

) patients with at least 20° combined extension deficit in metacarpophalangeal joint (MP) and/or proximal interphalangeal joint (PIP) in finger/fingers II-V 2) age > 18 years 3) palpable cord 4) provision of informed consent 5) ability to fill the Finnish versions of questionnaires

You may not qualify if:

Sponsors & Collaborators

Pirkanmaan hyvinvointialue
Type not reportedlead

Study Sites (6)

Central Finland Hospital District Central Finland Hospital Nova

Jyvaskyla, 40620, Finland

Toni Luokkala+3582695058 toni.luokkala@hyvaks.fi

Turku University Hospital

Turku, 20520, Finland

Markus Pääkkönen+35822660000 markus.paakkonen@varha.fi

HUS-Yhtymae

Helsinki, 00290, Finland

Susanna Stjernberg-Salmela+358504274955

Central Study Contacts

Olli Leppänen

+35831167745 olli.leppanen@pirha.fi

Study Design

Study Type: interventional
Phase: phase 3

Study Record Dates

First Submitted

August 19, 2024

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: 2024-515110-40-00
Data provider: European Medicines Agency (EMA)
Normalization version: ctis-v1

Open registry record

Source retrieved: 2026-10-30 05:18:32 UTC

Documents

Recruitment arrangements

NCT00528606

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture

Phase 3Completed

NCT01674634

Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures

Phase 3Completed

NCT00565019

Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Dupuytren's Contracture

Phase 3Completed

NCT03192020

Trial Comparing Treatment Strategies in Dupuytren's Contracture

Phase 4Active Not Recruiting

NCT00014742

Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease

Phase 3Completed

NCT01229436

Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)

Phase 3Completed

) recurrent contracture in the finger to be treated 2) neurologic condition causing the loss of function of the finger to be treated 3) contraindication for collagenase clostridium histolyticym (Xiapex/Xiaflex ®) 4) pregnant or breast feeding 5) TPED > 135° (Tubiana stage 472) in finger to be treated 6) rheumatoid arthritis 7) previous fracture in finger to be treated, which affects range of motion of MP or PIP joint 8) age > 80 years

Contact the study team to confirm eligibility.

susanna.stjernberg-salmela@hus.fi

Oulu University Hospital

Oulu, 90220, Finland

Janne Soikkeli+358505583855 janne.soikkeli@pohde.fi

Tampere University Hospital

Tampere, 33520, Finland

Olli Leppänen+3583311611 olli.leppanen@pirha.fi

Kuopio University Hospital

Kuopio, 70210, Finland

Matti Juntunen+358447174706 matti.juntunen@pshyvinvointialue.fi

Potilastiedote ja suostumus_09-12-2019

Liite tiedotteeseen_GDPR_2020-03-24

D1_Protocol EU CT 2024-515110-40-00 07Jul2025 CLEAN

Tutkimussuunnitelma_DK_lyhennelma

SmPC_Xiapex

Locations

FI(6)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Conditions

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (6)

Central Study Contacts

Study Design

Study Record Dates

Source record

Documents

Locations